The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).
 
Dana M Roque
No Relationships to Disclose
 
Stefania Bellone
No Relationships to Disclose
 
Eric R. Siegel
No Relationships to Disclose
 
Natalia Buza
No Relationships to Disclose
 
Elena Bonazzoli
No Relationships to Disclose
 
Adele Guglielmi
No Relationships to Disclose
 
Luca Zammataro
Consulting or Advisory Role - Kiromic
 
Nupur Nagarkatti
No Relationships to Disclose
 
Samir Zaidi
No Relationships to Disclose
 
Jungsoo Lee
No Relationships to Disclose
 
Peter E. Schwartz
No Relationships to Disclose
 
Elena Ratner
No Relationships to Disclose
 
Ludmil B. Alexandrov
No Relationships to Disclose
 
Akiko Iwasaki
No Relationships to Disclose
 
Yong Kong
No Relationships to Disclose
 
Eric Song
No Relationships to Disclose
 
Weilai Dong
No Relationships to Disclose
 
Julia Andrea Elvin
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Jungmin Choi
No Relationships to Disclose
 
Alessandro Santin
Consulting or Advisory Role - Merck; Tesaro
Research Funding - Boehringer Ingelheim (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Merck (Inst); Puma Biotechnology (Inst); R-Pharm (Inst); Tesaro (Inst)